By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Trigen Holdings AG 

Fraunhoferstrasse 9

Martinsried  Bavaria  82152  Germany
Phone: 44-0-20-7004-2630 Fax: 44-0-20-7004-2631



Start Up

Company News
Trigen Holdings AG Appoints Dr. Ayad Abdul-Ahad as Chief Executive Officer and Dr. Norbert Bender as Chief Medical Officer 7/23/2008 1:17:26 PM
Trigen Holdings AG's Innovative Platelet Adhesion Inhibitor, PR-15, Successfully Completes First-in-Man Phase I Study 5/1/2007 11:16:22 AM
Trigen Holdings AG Opens IND For The Initiation Of A Phase III Programme For Flovagatran (Formerly TGN 255), Its Novel Intravenous Direct Thrombin Inhibitor (DTI) 2/6/2007 10:34:20 AM
Trigen Holdings AG Obtains Exclusive License To GPVI Technology 1/23/2007 10:31:40 AM
Trigen Holdings AG Initiates Clinical Development With A Novel Therapeutic Protein, targeting Thrombosis And The Progression Of Atherosclerosis 12/13/2006 11:32:49 AM
Trigen Holdings AG Strengthens Its Supervisory Board With The Appointment Of Grahame Cook As A Non-Executive Director 9/27/2006 10:41:41 AM
Trigen Holdings AG Presents Phase II Results For Its Intravenous Direct Thrombin Inhibitor, TGN 255, For The Prevention Of Clotting During Hemodialysis 7/17/2006 12:05:35 PM
Trigen Completes €26.5 Million Financing Round10/19/2005 5:13:20 PM
Eurand (Milan, Italy) And Trigen Ltd. Announce A Development Collaboration For Trigen's Novel Oral Anticoagulant, TGN 16710/19/2005 5:12:17 PM